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Based on theoretically calculated comprehensive lipid libraries, in lipidomics as many
as 1000 multiple reaction monitoring (MRM) transitions can be monitored for each
single run. On the other hand, lipid analysis from each MRM chromatogram requires
tremendous manual efforts to identify and quantify lipid species. Isotopic peaks differing
by up to a few atomic masses further complicate analysis. To accelerate the identification
and quantification process we developed novel software, MRM-DIFF, for the differential
analysis of large-scale MRM assays. It supports a correlation optimized warping (COW)
algorithm to align MRM chromatograms and utilizes quality control (QC) sample datasets
to automatically adjust the alignment parameters. Moreover, user-defined reference
libraries that include the molecular formula, retention time, and MRM transition can be
used to identify target lipids and to correct peak abundances by considering isotopic peaks.
Here, we demonstrate the software pipeline and introduce key points for MRM-based
lipidomics research to reduce the mis-identification and overestimation of lipid profiles.
The MRM-DIFF program, example data set and the tutorials are downloadable at the
“Standalone software” section of the PRIMe (Platform for RIKEN Metabolomics, http://
prime.psc.riken.jp/) database website.
Keywords: multiple reaction monitoring, differential analysis, lipidomics, compound identification, isotopic peak
estimation
INTRODUCTION
Multiple reaction monitoring (MRM) during liquid chro-
matography coupled to a triple quadrupole mass spectrometer
(LC/QqQ/MS) is one of the standard methods in lipidomics
research (Shaner et al., 2009; Quehenberger et al., 2010). Its highly
sensitive and selective performance allows for the reliable mon-
itoring of lipid compounds of low abundance such as oxidized
lipids when MRM transitions, i.e., precursor- and product ion
pairs, are conditioned appropriately (Uchikata et al., 2012). The
key to success in lipidomics are lipid databases such as LIPID
MAPS (Fahy et al., 2007) and LipidBlast (Kind et al., 2013) that
provide in silico MS/MS spectra (and thereby MRM transitions)
of major lipid classes such as glycerolipids, phospholipids, and
sphingolipids. Thus, large-scale MRM assays monitor 500–1000
“theoretical” transitions on high-end QqQ/MS platforms (Ikeda
et al., 2008).
Compared to production scanning by LC quadrupole- time-
of-flight or Orbitrap MS (Q-TOF or Q-Orbitrap), the drawback
of such theoretical MRM assays is the uncertain reliability of com-
pound identification (Kind et al., 2013; Perez-Riverol et al., 2013).
This is largely due to the scan speed of QqQ/MS; it is not fast
enough to monitor three or more fragment ions to determine
their lipid class and acyl chain properties. The importance of diag-
nostic transitions has been emphasized in metabolomics (Stein
and Heller, 2006; Tsugawa et al., 2013) and it also applies for
lipidomics. For example, the notation of phosphatidyl choline
(PC) 38:2 [M+H]+ can match more than 100 acyl chain com-
binations, at least in theory, and they are expected to elute almost
simultaneously at the transition 814.6->184.1. Moreover, the
exact retention times for these of lipid isomers are currently
unavailable.
To solve this problem by informatics we presented a “pattern
recognition” approach (Sugimoto et al., 2012) for MRM assays.
We called it “differential analysis” for multiple chromatograms
because reliable ions and their isotopic ions can be estimated
by comparing multiple chromatograms. In addition, candidate
annotations can be reduced by statistical analyses before confirm-
ing each peak by authentic standards (Sugimoto et al., 2009).
In exchange, to accurately perform MRM based lipidomics
with the differential analysis approach, it necessitates the stan-
dardized management of all experimental processes from experi-
mental design to data processing. From the experimental design,
peak alignment parameters can be determined and signal inten-
sity drifts adjusted. Based on information of isotopic ions, peak-
identification can be corrected and quantification can be adjusted
because isotopic peaks from abundant ions sometimes overlap
with ions of minor lipids. To get around such processes for large
datasets we developed a software program that facilitates the
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differential analysis of large-scale MRM-based lipidomics. Our
Multiple Reaction Monitoring-based DIFFerential (MRM-DIFF)
analysis software supports chromatographic alignment and com-
pound identification with estimation of isotopic peaks. Here we
introduce a systematic strategy to perform differential analysis
by MRM-DIFF with pooled quality control (QC) datasets. The
pooled QC data, a mixture of small aliquots from each sam-
ple, were originally used to correct MS intensity drifts across a
given analytical batch (Dunn et al., 2011). We use them to select
a suitable “reference” for chromatographic alignment and peak
quantification and demonstrate the advantages of our strategy
with 37 serum datasets with 189 MRM transitions each.
RESULTS
Figure 1 is a summary of our data processing method. After
LC conditioning, pooled QC samples are analyzed at each fifth
sample injection (Figure 1A). Based on the “chromatographic
centroid” concept (see Theory below), one QC dataset is auto-
matically selected from among all raw data files to serve as the
reference. All other chromatograms, including the QC datasets,
are aligned to the selected reference chromatogram by cor-
relation optimized warping (COW), a popular dynamic pro-
gramming algorithm for non-linear chromatographic alignment
(Figure 1B) (Nielsen et al., 1998; Tomasi et al., 2004). Then a user-
defined library of the retention time, theMRM transition, and the
molecular formula for compounds is imported to perform peak
identification and isotopic estimation. The program also imple-
ments a peak detection algorithm and uses the abundance of
detected peaks for multivariate analysis (Figure 1C). The QC data
are also exploited in the peak detection process. Since the pooled
QC data are expected to contain all detectable lipid compounds
from all samples, missing peaks, i.e., existing but unidentified
peaks in some biological samples, can be interpolated based on
the peak widths and retention times of the QC peaks. The algo-
rithmic detail is described in the Theory section. The graphic
user interface assists the workflow and contributes to a better
understanding of compound identification and peak quantifica-
tion (Figure 1C). The abundances of isotopic peaks are resolved
and signal intensity drifts are corrected with LOESS (Cleveland,
1979) and cubic spline before statistical analyses (Figure 1D).
In our proof-of-concept analysis, MRM-DIFF successfully
profiled 259 lipids and 677 unknown metabolites in human-,
mouse-, and rat-serum using 189 MRM transitions (see
Supplementary File 1 for all profiles). Details of the MRM tran-
sitions and retention times of our focused lipids are shown
in Table 1. The time for data processing was less than 20min
(Intel Core i7-4700MQ CPU at 2.4Gb and 8Gb RAM with
Windows 8.1). For a few un-annotated peaks, the identification
results were manually curated through the graphical user inter-
face (GUI) of theMRM-DIFF program. The lipid coverage for the
PC and phosphatidylethanolamine (PE) species on LC/QqQ/MS
exceeded previously reported results (Psychogios et al., 2011).
The advantage of our strategy is the extensive use of isotopic
peaks to reduce mis-identification and over-quantification. For
example, in the 796.6–184.1 MRM chromatogram (Figure 2) the
isotopic ion M+2 of highly abundant O-alkyl PC 37:5e (MW
794.6) wasmonitored at 25.4min. Likewise, the isotopic ionM+2
of O-alkenyl phosphatidylcholine PC 37:5p (MW794.6) existed at
26.1min but the isotope contributed only 16% of the total abun-
dance, leaving 84% for another unidentified isomer. Therefore, to
distinguish the isomer- and isotopic-peaks objectively, the MRM
transitions for all patterns of different degrees of unsaturation (a
ladder of 2m/z decrements) must be monitored. The 796.6–184.1
MRM chromatogram contained six isomeric peaks including
two unannotated peaks (24.6 and 27.3min) and one isotopic
peak from MW 794.6 (25.4min). In our serum dataset, 71 sig-
nificant peaks were dismissed as pure isotopic peaks of higher
abundances.
The second advantage is the smart selection of a QC refer-
ence for COW-based chromatographic alignment. The accurate
alignment of MRM chromatograms is necessary for accurate lipid
quantification. For reverse-phase LC methods, two user-defined
parameters in the COW algorithm, “segment size” and “warp
slack,” can be set as the peak width (0.5min in our study) and
as “1 or 2,” respectively. This leaves the selection of the reference
chromatogram as the only critical parameter in the algorithm
(Figure 3). The reference chromatogram should be positioned
at the center of all chromatograms to be aligned. Moreover, the
higher the chromatographic similarity, the better is the align-
ment. Therefore, we created pooled QC datasets as the average
of all biological samples and chose one representative QC datum
whose chromatogram was closest to the midpoint of all chro-
matograms (chromatographic centroid). The automatic selection
picked the suitable reference and corrected the retention time
drifts efficiently in our demonstration. Our example data sets are
downloadable at http://prime.psc.riken.jp/.
The third advantage of our strategy is the use of LOESS and
cubic spline normalization to reduce MS signal drifts in an ana-
lytical batch (Dunn et al., 2011). The LOESS smoother is first
applied to the pooled QC datasets in the order of injection. Then
the abundances of each metabolite in the biological samples are
corrected by cubic spline interpolated from the abundances in
the smoothed QC data. The score plot of principal component
analysis (PCA) indicated a better decrease in the deviation of
clustering results than when alternative normalization using an
internal standard, PC (12:0/12:0), was applied (Figure 4). There
is no consensus for normalization methods in the LIPID MAPS
consortium (Ivanova et al., 2007) and MRM-DIFF provides for
the application of both methods for abundance normalization.
Most lipid compounds are commonly detected among human-,
mouse-, and rat-sera. It seems that anabolic or cleavage enzymes
such as fatty acid synthase and lipase are conserved at least for
the major lipids identified in our study. In addition, the fatty
acid varieties of human serum conjugated in glycerophospho-
lipids were richer than in the other two species in which many
PE species were not detected (Supplementary File 1).
DISCUSSION
We demonstrated a different analysis with the systematic strat-
egy for MRM-based lipid profiling. Our MRM-DIFF software
program semi-automatically performs lipid identification and
quantification of large scale MRM datasets. It also considers
isotopic peaks to reduce false-positives and mis-quantifications.
While pooled QC data are not always necessary, they help to find
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FIGURE 1 | Differential analysis strategy for large-scale MRM-based
lipidomics. (A) Since this strategy utilizes pooled quality control (QC) datasets
for data processing methods, pooled QCs are injected at every five biological
samples. (B) After reference file selection based on chromatograms of pooled
QC datasets, MRM chromatograms are adjusted to the MRM chromatogram
reference file by correlation optimized warping based non-linear alignment. (C)
The data processing results including compound identifications and isotopic
peak estimations can be monitored in the MRM-DIFF program. The graphical
user interface facilitates manual curation of the results as well as validation of
identification accuracy. (D) In addition to principal component analysis,
MRM-DIFF supports standardization methods including isotopic peak
reduction and LOESS/cubic spline based normalization.
system parameters and to correct MS signal intensities for a better
performance.
The advantage of pattern recognition from overlays is that
many candidates can be detected as unknown or identified com-
pounds (Ma et al., 2008; Vallejo et al., 2009). In this study, 677
unknown compounds were reliably detected in serum samples
from three species. Such metabolites can be validated one-by-one
by authentic standards or by high-resolution MS/MS platforms
with structure prediction. In addition, the retention time of lipids
in reverse phase LC methods can be theoretically estimated by the
quantitative structure-retention relationship (QSRR) (Kaliszan,
2007; Audain et al., 2014; Cao et al., 2014), and its accuracy is
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Table 1 | Detailed MRM conditions and retention times of targeted lipids.
Name Formula Precursor Product Retention Ion Event Dwell Q1 Pre Collision Q3 Pre
m/z m/z time [min] mode ID time [ms] bias [V] energy [V] bias [V]
lysoPC 14:0 (sn-2) C22H46NO7P 468.3 184.1 6.34 Positive 1 5 20 20 25
lysoPC 14:0 (sn-1) C22H46NO7P 468.3 184.1 7.03 Positive 1 5 20 20 25
lysoPC 15:0 (sn-2) C23H48NO7P 482.3 184.1 7.88 Positive 2 5 20 20 25
lysoPC 15:0 (sn-1) C23H48NO7P 482.3 184.1 8.65 Positive 2 5 20 20 25
lysoPC 16:0e C24H52NO6P 482.3 184.1 12.20 Positive 2 5 20 20 25
lysoPC 15:1 (sn-1) C23H48NO7P 480.3 184.1 7.23 Positive 3 5 20 20 25
lysoPC 16:0p C24H50NO6P 480.3 184.1 11.86 Positive 3 5 20 20 25
lysoPC 16:0 (sn-2) C23H46NO7P 496.3 184.1 9.58 Positive 4 5 20 20 25
lysoPC 16:0 (sn-1) C24H50NO7P 496.3 184.1 10.40 Positive 4 5 20 20 25
lysoPC 16:1 (sn-2) C24H48NO7P 494.3 184.1 7.29 Positive 5 5 20 20 25
lysoPC 16:1 (sn-1) C24H48NO7P 494.3 184.1 8.00 Positive 5 5 20 20 25
lysoPC 17:0 (sn-2) C25H52NO7P 510.4 184.1 11.29 Positive 6 5 20 20 25
lysoPC 17:0 (sn-1) C25H52NO7P 510.4 184.1 12.10 Positive 6 5 20 20 25
lysoPC 17:1 (sn-2) C25H50NO7P 508.3 184.1 8.89 Positive 7 5 20 20 25
lysoPC 17:1 (sn-1) C25H50NO7P 508.3 184.1 9.62 Positive 7 5 20 20 25
lysoPC 18:0p C26H54NO6P 508.3 184.1 15.07 Positive 7 5 20 20 25
lysoPC 18:0 (sn-2) C26H54NO7P 524.4 184.1 12.93 Positive 8 5 20 20 25
lysoPC 18:0 (sn-1) C26H54NO7P 524.4 184.1 13.72 Positive 9 5 20 20 25
lysoPC 18:1 (sn-2) C26H52NO7P 522.4 184.1 10.51 Positive 10 5 20 20 25
lysoPC 18:1 (sn-1) C26H52NO7P 522.4 184.1 11.27 Positive 10 5 20 20 25
lysoPC 18:2 (sn-2) C26H50NO7P 520.3 184.1 8.53 Positive 11 5 20 20 25
lysoPC 18:2 (sn-1) C26H50NO7P 520.3 184.1 9.27 Positive 11 5 20 20 25
lysoPC 18:3 (sn-2) C26H48NO7P 518.3 184.1 6.95 Positive 12 5 20 20 25
lysoPC 18:3 (sn-1) C26H48NO7P 518.3 184.1 7.66 Positive 12 5 20 20 25
lysoPC 19:0 (sn-2) C27H56NO7P 538.4 184.1 14.51 Positive 13 5 20 20 25
lysoPC 19:0 (sn-1) C27H56NO7P 538.4 184.1 15.27 Positive 13 5 20 20 25
lysoPC 20:0 (sn-2) C28H58NO7P 552.4 184.1 15.98 Positive 14 5 20 20 25
lysoPC 20:0 (sn-1) C28H58NO7P 552.4 184.1 16.67 Positive 14 5 20 20 25
lysoPC 20:1 (sn-2) C28H56NO7P 550.4 184.1 13.58 Positive 15 5 20 20 25
lysoPC 20:1 (sn-1) C28H56NO7P 550.4 184.1 14.36 Positive 15 5 20 20 25
lysoPC 20:2 (sn-2) C28H54NO7P 548.4 184.1 11.60 Positive 16 5 20 20 25
lysoPC 20:2 (sn-1) C28H54NO7P 548.4 184.1 12.38 Positive 16 5 20 20 25
lysoPC 20:3 (sn-2) C28H52NO7P 546.4 184.1 9.86 Positive 17 5 20 20 25
lysoPC 20:3 (sn-1) C28H52NO7P 546.4 184.1 10.57 Positive 17 5 20 20 25
lysoPC 20:4 (sn-2) C28H50NO7P 544.3 184.1 8.63 Positive 18 5 20 20 25
lysoPC 20:4 (sn-1) C28H50NO7P 544.3 184.1 9.29 Positive 18 5 20 20 25
lysoPC 20:5 (sn-2) C28H48NO7P 542.3 184.1 7.09 Positive 19 5 20 20 25
lysoPC 20:5 (sn-1) C28H48NO7P 542.3 184.1 7.70 Positive 19 5 20 20 25
lysoPC 22:0 (sn-2) C30H62NO7P 580.4 184.1 18.53 Positive 20 5 20 20 25
lysoPC 22:0 (sn-1) C30H62NO7P 580.4 184.1 19.17 Positive 20 5 20 20 25
lysoPC 22:4 (sn-2) C30H54NO7P 572.4 184.1 11.23 Positive 21 5 20 20 25
lysoPC 22:4 (sn-1) C30H54NO7P 572.4 184.1 11.92 Positive 21 5 20 20 25
lysoPC 22:6 (sn-2) C30H50NO7P 568.3 184.1 8.69 Positive 22 5 20 20 25
lysoPC 22:6 (sn-1) C30H50NO7P 568.3 184.1 9.33 Positive 22 5 20 20 25
PC 24:0; PC 12:0/12:0 (IS) C32H64NO8P 622.4 184.1 17.70 Positive 23 5 24 26 26
PC 30:0; PC 14:0/16:0 C38H76NO8P 706.5 184.1 23.39 Positive 24 5 24 26 26
PC 30:1; PC 14:0/16:1 C38H74NO8P 704.5 184.1 22.16 Positive 25 5 24 26 26
PC 31:0; PC 15:0/16:0 C39H78NO8P 720.5 184.1 24.16 Positive 26 5 24 26 26
PC 32:0e; PC 16:0e/16:0 C39H80NO7P 720.5 184.1 26.02 Positive 26 5 24 26 26
PC 31:1; PC 15:0/16:1 C39H76NO8P 718.5 184.1 22.97 Positive 27 5 24 26 26
PC 32:0p; PC 16:0p/16:0 C39H76NO7P 718.5 184.1 25.72 Positive 27 5 24 26 26
(Continued)
Frontiers in Genetics | Bioinformatics and Computational Biology January 2015 | Volume 5 | Article 471 | 4
Tsugawa et al. MRM-DIFF: software for MRM-based lipidomics
Table 1 | Continued
Name Formula Precursor Product Retention Ion Event Dwell Q1 Pre Collision Q3 Pre
m/z m/z time [min] mode ID time [ms] bias [V] energy [V] bias [V]
PC 32:0; PC 16:0/16:0 C40H80NO8P 734.6 184.1 24.97 Positive 28 5 24 26 26
PC 32:1; PC 14:0/18:1 or
16:0/16:1
C40H78NO8P 732.5 184.1 23.74 Positive 29 5 24 26 26
PC 32:2; PC 14:0/18:2 or
16:1/16:1
C40H76NO8P 730.5 184.1 22.69 Positive 30 5 24 26 26
PC 33:0; PC 17:0/16:0 or
18:0/15:0
C41H82NO8P 748.6 184.1 25.74 Positive 31 5 24 26 26
PC 34:0e; PC 18:0e/16:0 C41H84NO7P 748.6 184.1 27.88 Positive 31 5 24 26 26
PC 33:1; PC 15:0/18:1 or
16:0/17:1
C41H80NO8P 746.6 184.1 24.50 Positive 32 5 24 26 26
PC 34:1e; PC 18:0e/16:1
or 18:1e/16:0
C41H82NO7P 746.6 184.1 26.32 Positive 32 5 24 26 26
PC 33:2; PC 15:0/18:2 C41H78NO8P 744.6 184.1 23.47 Positive 33 5 24 26 26
PC 34:2e; PC 16:0e/18:2 C41H80NO7P 744.6 184.1 24.97 Positive 33 5 24 26 26
PC 34:2e; PC 16:1e/18:1 C41H80NO7P 744.6 184.1 25.23 Positive 33 5 24 26 26
PC 34:0; PC 16:0/18:0 C42H84NO8P 762.6 184.1 26.67 Positive 34 5 24 26 26
PC 34:1; PC 16:0/18:1 C42H82NO8P 760.6 184.1 25.27 Positive 35 5 24 26 26
PC 34:2; PC 16:0/18:2 or
16:1/18:1
C42H80NO8P 758.6 184.1 24.22 Positive 36 5 24 26 26
PC 34:3; PC 14:0/20:3 C42H78NO8P 756.6 184.1 23.05 Positive 37 5 24 26 26
PC 34:3; PC 16:0/18:3 or
16:1/18:2
C42H78NO8P 756.6 184.1 23.41 Positive 37 5 24 26 26
PC 34:4; PC 14:0/20:4 or
16:1/18:3
C42H76NO8P 754.5 184.1 22.62 Positive 38 5 24 26 26
PC 34:5; PC 14:0/20:5 C42H74NO8P 752.5 184.1 21.74 Positive 39 5 24 26 26
PC 35:1; PC 16:0/19:1 or
17:0/18:1 or 17:1/18:0
C43H84NO8P 774.6 184.1 26.06 Positive 40 5 24 26 26
PC 36:2e; PC 16:0e/20:2 C43H84NO7P 772.6 184.1 27.01 Positive 41 5 24 26 26
PC 35:2; PC 17:0/18:2 or
17:1/18:1
C43H82NO8P 772.6 184.1 25.03 Positive 41 5 24 26 26
PC 35:2e; PC 18:0p/18:1
or 18:1e/18:1
C43H84NO7P 772.6 184.1 26.67 Positive 41 5 24 26 26
PC 35:3; PC 17:1/18:2 C43H80NO8P 770.6 184.1 23.82 Positive 42 5 24 26 26
PC 36:3e; PC 18:1e/18:2 C43H82NO7P 770.6 184.1 25.55 Positive 42 5 24 26 26
PC 36:3e; PC 18:2e/18:1 C43H82NO7P 770.6 184.1 25.80 Positive 42 5 24 26 26
PC 35:4; PC 15:0/20:4 C43H78NO8P 768.6 184.1 23.37 Positive 43 5 24 26 26
PC 36:4e; PC 16:1e/20:3 C43H78NO8P 768.6 184.1 25.11 Positive 43 5 24 26 26
PC 35:5; PC 15:0/20:5 C43H76NO8P 766.5 184.1 22.54 Positive 44 5 24 26 26
PC 36:5e; PC 16:0e/20:5 C43H78NO7P 766.5 184.1 24.30 Positive 44 5 24 26 26
PC 36:4p; PC 16:0p/20:4 C43H76NO7P 766.5 184.1 24.83 Positive 44 5 24 26 26
PC 38:6p; PC 16:0p/22:6 C44H88NO7P 790.6 184.1 29.41 Positive 45 5 24 26 26
PC 36:0; PC 18:0/18:0 C44H88NO8P 790.6 184.1 28.66 Positive 45 5 24 26 26
PC 36:1; PC 18:0/18:1 C44H86NO8P 788.6 184.1 27.07 Positive 46 5 24 26 26
PC 36:2; PC 18:0/18:2 or
18:1/18:1
C44H84NO8P 786.6 184.1 25.82 Positive 47 5 24 26 26
PC 36:3; PC 16:0/20:3 or
18:0/18:3 or 18:1/18:2
C44H82NO8P 784.6 184.1 24.66 Positive 48 5 24 26 26
PC 36:4; PC 16:0/20:4 or
16:1/20:3
C44H80NO8P 782.6 184.1 24.14 Positive 49 5 24 26 26
PC 36:4; PC 18:1/18:3 or
18:2/18:2
C44H80NO8P 782.6 184.1 23.55 Positive 49 5 24 26 26
PC 36:5; PC 14:0/22:5 or
16:0/20:5 or 16:1/20:4
C44H78NO8P 780.6 184.1 23.29 Positive 50 5 24 26 26
(Continued)
www.frontiersin.org January 2015 | Volume 5 | Article 471 | 5
Tsugawa et al. MRM-DIFF: software for MRM-based lipidomics
Table 1 | Continued
Name Formula Precursor Product Retention Ion Event Dwell Q1 Pre Collision Q3 Pre
m/z m/z time [min] mode ID time [ms] bias [V] energy [V] bias [V]
PC 36:5; PC 18:2/18:3 C44H78NO8P 780.6 184.1 22.93 Positive 50 5 24 26 26
PC 36:6; PC 14:0/22:6 C44H76NO8P 778.5 184.1 22.48 Positive 51 5 24 26 26
PC 36:6; PC 16:1/20:5 C44H76NO8P 778.5 184.1 22.14 Positive 51 5 24 26 26
PC 37:1; PC 18:0/19:1 or
19:0/18:1
C45H88NO8P 802.6 184.1 27.96 Positive 52 5 24 26 26
PC 37:2; PC 18:1/19:1 or
18:2/19:0
C45H86NO8P 800.6 184.1 26.70 Positive 53 5 24 26 26
PC 37:3; PC 17:0/20:3 or
19:1/18:2
C45H84NO8P 798.6 184.1 25.59 Positive 54 5 24 26 26
PC 37:4; PC 17:0/20:4 C45H82NO8P 796.6 184.1 24.91 Positive 55 5 24 26 26
PC 38:4e; PC 18:0e/20:4 C45H84NO7P 796.6 184.1 26.85 Positive 55 5 24 26 26
PC 38:4e; PC 18:1e/20:3 C45H84NO7P 796.6 184.1 26.40 Positive 55 5 24 26 26
PC 38:5e; PC 16:0e/22:5
or 18:0e/20:5
C45H82NO7P 794.6 184.1 25.41 Positive 56 5 24 26 26
PC 37:5; PC 17:0/20:5 or
17:1/20:4
C45H80NO8P 794.6 184.1 24.10 Positive 56 5 24 26 26
PC 38:4p; PC 18:0p/20:4 C45H80NO7P 794.6 184.1 26.08 Positive 56 5 24 26 26
PC 37:6; PC 15:0/22:6 C45H78NO8P 792.6 184.1 23.29 Positive 57 5 24 26 26
PC 38:6e; PC 16:0e/22:6 C45H80NO7P 792.6 184.1 25.13 Positive 57 5 24 26 26
PC 38:6e; PC 18:1e/20:5 C45H80NO7P 792.6 184.1 24.38 Positive 57 5 24 26 26
PC 38:1; PC 18:1/20:0 C46H90NO8P 816.6 184.1 29.01 Positive 58 5 24 26 26
PC 38:2; PC 16:0/22:2 C46H88NO8P 814.6 184.1 27.22 Positive 59 5 24 26 26
PC 38:2; PC 18:0/20:2 C46H88NO8P 814.6 184.1 27.49 Positive 59 5 24 26 26
PC 38:3; PC 18:0/20:3 or
18:1/20:2
C46H86NO8P 812.6 184.1 26.44 Positive 60 5 24 26 26
PC 38:4; PC 18:0/20:4 C46H84NO8P 810.6 184.1 25.73 Positive 61 5 24 26 26
PC 38:4; PC 18:1/20:3 C46H84NO8P 810.6 184.1 25.37 Positive 61 5 24 26 26
PC 38:5; PC 18:0/20:5 C46H82NO8P 808.6 184.1 24.86 Positive 62 5 24 26 26
PC 38:5; PC 18:1/20:4 C46H82NO8P 808.6 184.1 24.46 Positive 62 5 24 26 26
PC 38:6; PC 16:0/22:6 or
18:2/20:4
C46H80NO8P 806.6 184.1 24.02 Positive 63 5 24 26 26
PC 38:7; PC 16:1/22:6 or
18:2/20:5
C46H78NO8P 804.6 184.1 22.62 Positive 64 5 24 26 26
PC 39:3; PC 19:0/20:3 C47H88NO8P 826.6 184.1 27.33 Positive 65 5 24 26 26
PC 39:6; PC 17:0/22:6 C47H84NO8P 820.6 184.1 24.76 Positive 66 5 24 26 26
PC 40:5p; PC 18:0p/22:5 C47H84NO7P 820.6 184.1 26.60 Positive 66 5 24 26 26
PC 40:6e; PC 18:1e/22:5 C47H86NO7P 820.6 184.1 25.71 Positive 66 5 24 26 26
PC 39:7; PC 17:1/22:6 C47H80NO8P 818.6 184.1 24.18 Positive 67 5 24 26 26
PC 40:7e; PC 18:1e/22:6 C47H82NO7P 818.6 184.1 25.31 Positive 67 5 24 26 26
PC 40:1; PC 18:1/22:0 C48H94NO8P 844.7 184.1 31.51 Positive 68 5 24 26 26
PC 40:4; PC 18:0/22:4 or
20:1/20:3
C48H88NO8P 838.6 184.1 27.57 Positive 69 5 24 26 26
PC 40:5; PC 18:0/22:5 C48H86NO8P 836.6 184.1 26.54 Positive 69 5 24 26 26
PC 40:6; PC 18:0/22:6 C48H84NO8P 834.6 184.1 25.59 Positive 70 5 24 26 26
PC 40:6; PC 18:1/22:5 or
20:2/20:4
C48H84NO8P 834.6 184.1 25.13 Positive 70 5 24 26 26
PC 40:7; PC 18:1/22:6 C48H82NO8P 832.6 184.1 24.28 Positive 71 5 24 26 26
PC 40:7; PC 20:3/20:4 C48H82NO8P 832.6 184.1 23.91 Positive 71 5 24 26 26
PC 40:8; PC 20:4/20:4 C48H80NO8P 830.6 184.1 23.27 Positive 72 5 24 26 26
PC 41:6; PC 19:0/22:6 C49H86NO8P 848.6 184.1 26.42 Positive 73 5 24 26 26
lysoPE 14:0 (sn-2) C19H40NO7P 426.3 285.3 6.40 Positive 74 5 17 15 25
lysoPE 14:0 (sn-1) C19H40NO7P 426.3 285.3 7.25 Positive 74 5 17 15 25
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Name Formula Precursor Product Retention Ion Event Dwell Q1 Pre Collision Q3 Pre
m/z m/z time [min] mode ID time [ms] bias [V] energy [V] bias [V]
lysoPE 16:0 (sn-2) C21H44NO7P 454.3 313.3 9.71 Positive 75 5 17 15 25
lysoPE 16:0 (sn-1) C21H44NO7P 454.3 313.3 10.52 Positive 75 5 17 15 25
lysoPE 17:0 (sn-2) C22H46NO7P 468.3 327.3 11.45 Positive 76 5 17 15 25
lysoPE 17:0 (sn-1) C22H46NO7P 468.3 327.3 12.22 Positive 76 5 17 15 25
lysoPE 18:0e C23H50NO6P 468.3 327.3 15.47 Positive 76 5 17 15 25
lysoPE 18:0 (sn-2) C23H48NO7P 482.3 341.3 13.06 Positive 77 5 17 15 25
lysoPE 18:0 (sn-1) C23H48NO7P 482.3 341.3 13.83 Positive 77 5 17 15 25
lysoPE 18:1 (sn-2) C23H46NO7P 480.3 339.3 10.66 Positive 78 5 17 15 25
lysoPE 18:1 (sn-1) C23H46NO7P 480.3 339.3 11.35 Positive 78 5 17 15 25
lysoPE 18:2 (sn-2) C23H44NO7P 478.3 337.3 8.62 Positive 79 5 17 15 25
lysoPE 18:2 (sn-1) C23H44NO7P 478.3 337.3 9.37 Positive 79 5 17 15 25
lysoPE 20:0 (sn-2) C25H52NO7P 510.4 369.4 15.99 Positive 80 5 17 15 25
lysoPE 20:0 (sn-1) C25H52NO7P 510.4 369.4 16.74 Positive 80 5 17 15 25
lysoPE 20:1 (sn-2) C25H50NO7P 508.3 367.3 13.75 Positive 81 5 17 15 25
lysoPE 20:1 (sn-1) C25H50NO7P 508.3 367.3 14.42 Positive 81 5 17 15 25
lysoPE 20:3 (sn-2) C25H46NO7P 504.3 363.3 10.07 Positive 82 5 17 15 25
lysoPE 20:3 (sn-1) C25H46NO7P 504.3 363.3 10.70 Positive 82 5 17 15 25
lysoPE 20:4 (sn-2) C25H44NO7P 502.3 361.3 8.70 Positive 83 5 17 15 25
lysoPE 20:4 (sn-1) C25H44NO7P 502.3 361.3 9.35 Positive 83 5 17 15 25
lysoPE 20:5 (sn-1) C25H42NO7P 500.3 359.3 7.10 Positive 84 5 17 15 25
lysoPE 20:5 (sn-2) C25H42NO7P 500.3 359.3 7.77 Positive 84 5 17 15 25
lysoPE 22:6 (sn-1) C27H44NO7P 526.3 385.3 8.88 Positive 85 5 17 15 25
lysoPE 22:6 (sn-2) C27H44NO7P 526.3 385.3 9.51 Positive 85 5 17 15 25
PE 32:0; PE 16:0/16:0 C37H74NO8P 692.5 551.5 24.94 Positive 86 5 20 20 30
PE 32:1; PE 14:0/18:1 or
16:0/16:1
C37H72NO8P 690.5 549.5 23.73 Positive 87 5 20 20 30
PE 32:2; PE 14:0/18:2 C37H70NO8P 688.5 547.5 22.60 Positive 88 5 20 20 30
PE 33:1; PE 15:0/18:1 C38H74NO8P 704.6 563.6 24.50 Positive 89 5 20 20 30
PE 34:1e; PE 16:0e/18:1 C38H76NO7P 704.6 563.6 26.32 Positive 89 5 20 20 30
PE 33:2; PE 15:0/18:2 C38H72NO8P 702.5 561.5 23.27 Positive 90 5 20 20 30
PE 34:1p; PE 16:0p/18:1 C38H72NO7P 702.5 561.5 25.23 Positive 90 5 20 20 30
PE 34:0; PE 16:0/18:0 C39H78NO8P 720.6 579.6 26.56 Positive 91 5 20 20 30
PE 34:1; PE 16:0/18:1 C39H76NO8P 718.5 577.5 25.21 Positive 92 5 20 20 30
PE 34:2; PE 16:0/18:2 or
16:1/18:1
C39H74NO8P 716.5 575.5 24.26 Positive 93 5 20 20 30
PE 34:3; PE 16:0/18:3 C39H72NO8P 714.5 573.5 23.00 Positive 94 5 20 20 30
PE 34:3; PE 16:1/18:2 C39H72NO8P 714.5 573.5 23.43 Positive 94 5 20 20 30
PE 35:1; PE 17:0/18:1 C40H78NO8P 732.6 591.6 26.05 Positive 95 5 20 20 30
PE 36:1e; PE 18:0e/18:1 C40H80NO7P 732.6 591.6 28.22 Positive 95 5 20 20 30
PE 35:2; PE 17:0/18:2 C40H76NO8P 730.5 589.5 25.04 Positive 96 5 20 20 30
PE 36:2e; PE 18:0e/18:2 C40H78NO7P 730.5 589.5 27.04 Positive 96 5 20 20 30
PE 36:1p; PE 18:0p/18:1 C40H76NO7P 730.5 589.5 27.97 Positive 96 5 20 20 30
PE 35:3; PE 17:1/18:2 C40H74NO8P 728.5 587.5 24.00 Positive 97 5 20 20 30
PE 36:2p or 36:3e; PE
18:0p/18:2 or 18:0e/18:3
or 18:1p/18:1
C40H74NO7P 728.5 587.5 26.66 Positive 97 5 20 20 30
PE 36:3p or 36:4e; PE
16:0p/20:3 or 16:0e/20:4
C40H72NO7P 726.5 585.5 25.14 Positive 98 5 20 20 30
PE 36:4p; PE 16:0p/20:4 C40H70NO7P 724.5 583.5 24.80 Positive 99 5 20 20 30
PE 36:5p; PE 16:0p/20:5 C40H68NO7P 722.5 581.5 23.70 Positive 100 5 20 20 30
PE 36:1; PE 16:0/20:1 or
18:0/18:1
C41H80NO8P 746.6 605.6 27.00 Positive 101 5 20 20 30
(Continued)
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Name Formula Precursor Product Retention Ion Event Dwell Q1 Pre Collision Q3 Pre
m/z m/z time [min] mode ID time [ms] bias [V] energy [V] bias [V]
PE 36:2; PE 18:0/18:2 or
18:1/18:1
C41H78NO8P 744.6 603.6 25.79 Positive 102 5 20 20 30
PE 36:3; PE 18:1/18:2 C41H76NO8P 742.5 601.5 24.70 Positive 103 5 20 20 30
PE 36:4; PE 16:0/20:4 C41H74NO8P 740.5 599.5 24.15 Positive 104 5 20 20 30
PE 36:4; PE 18:2/18:2 C41H74NO8P 740.5 599.5 23.55 Positive 104 5 20 20 30
PE 36:5; PE 16:0/20:5 C41H72NO8P 738.5 597.5 23.33 Positive 105 5 20 20 30
PE 36:5; PE 18:2/18:3 C41H72NO8P 738.5 597.5 23.00 Positive 105 5 20 20 30
PE 36:6; PE 16:1/20:5 C41H70NO8P 736.5 595.5 22.00 Positive 106 5 20 20 30
PE 37:2; PE 19:0/18:2 C42H80NO8P 758.6 617.6 26.60 Positive 107 5 20 20 30
PE 38:1e; PE 20:0e/18:1 C42H82NO7P 758.6 617.6 29.04 Positive 107 5 20 20 30
PE 37:3; PE 17:0/20:3 C42H78NO8P 756.6 615.6 25.50 Positive 108 5 20 20 30
PE 37:4; PE 17:0/20:4 C42H76NO8P 754.5 613.5 24.94 Positive 109 5 20 20 30
PE 38:4e; PE 18:0e/20:4
or 20:0e/18:4 or
20:1e/18:3
C42H78NO7P 754.5 613.5 26.88 Positive 109 5 20 20 30
PE 38:4e; PE 18:1e/20:3 C42H78NO7P 754.5 613.5 26.38 Positive 109 5 20 20 30
PE 38:4p; PE 16:0p/22:4
or 18:1p/20:3
C42H74NO7P 752.5 611.5 25.45 Positive 110 5 20 20 30
PE 37:5; PE 17:1/20:4 C42H74NO8P 752.5 611.5 23.30 Positive 110 5 20 20 30
PE 38:4p; PE 18:0p/20:4 C42H74NO7P 752.5 611.5 26.48 Positive 110 5 20 20 30
PE 38:5p or 38:6e; PE
18:0p/20:5 or 18:1p/20:4
or 16:0e/22:6
C42H72NO7P 750.5 609.5 24.92 Positive 111 5 20 20 30
PE 38:6p; PE 16:0p/22:6 C42H70NO7P 748.6 607.6 24.64 Positive 112 5 20 20 30
PE 38:1; PE 18:0/20:1 C43H84NO8P 774.6 633.6 28.94 Positive 113 5 20 20 30
PE 38:2; PE 18:1/20:1 C43H82NO8P 772.6 631.6 27.38 Positive 114 5 20 20 30
PE 38:2; PE 20:0/18:2 C43H82NO8P 772.6 631.6 27.49 Positive 114 5 20 20 30
PE 38:3; PE 18:0/20:3 C43H80NO8P 770.6 629.6 26.39 Positive 115 5 20 20 30
PE 38:4; PE 16:0/22:4 C43H78NO8P 768.6 627.6 25.06 Positive 116 5 20 20 30
PE 38:4; PE 18:0/20:4 C43H78NO8P 768.6 627.6 25.69 Positive 116 5 20 20 30
PE 38:4; PE 18:1/20:3 or
18:2/20:2
C43H78NO8P 768.6 627.6 25.32 Positive 116 5 20 20 30
PE 38:5; PE 18:0/20:5 C43H76NO8P 766.5 625.5 24.86 Positive 117 5 20 20 30
PE 38:5; PE 18:1/20:4 C43H76NO8P 766.5 625.5 24.47 Positive 117 5 20 20 30
PE 38:6; PE 16:0/22:6 or
16:1/22:5 or 20:2/18:4
C43H74NO8P 764.5 623.5 23.97 Positive 118 5 20 20 30
PE 38:6; PE 18:1/20:5 or
18:2/20:4
C43H74NO8P 764.5 623.5 23.44 Positive 118 5 20 20 30
PE 38:7; PE 16:1/22:6 or
18:2/20:5
C43H72NO8P 762.5 621.5 22.40 Positive 119 5 20 20 30
PE 40:4e; PE 18:0e/22:4
or 20:0e/20:4
C44H82NO7P 782.6 641.6 28.86 Positive 120 5 20 20 30
PE 39:4; PE 19:0/20:4 C44H80NO8P 782.6 641.6 26.11 Positive 120 5 20 20 30
PE 39:5; PE 17:0/22:5 C44H78NO8P 780.6 639.6 25.06 Positive 121 5 20 20 30
PE 39:6; PE 17:0/22:6 C44H76NO8P 778.5 637.5 24.50 Positive 122 5 20 20 30
PE 40:5p; PE 18:0p/22:5
or 18:1p/22:4
C44H76NO7P 778.5 637.5 27.36 Positive 122 5 20 20 30
PE 39:7; PE 17:1/22:6 C44H74NO8P 776.5 635.5 23.36 Positive 123 5 20 20 30
PE 40:6p; PE 18:0p/22:6
or 18:1p/22:5
C44H74NO7P 776.5 635.5 26.23 Positive 123 5 20 20 30
PE 40:1; PE 22:0/18:1 C45H88NO8P 802.6 661.6 30.20 Positive 124 5 20 20 30
PE 40:2; PE 18:1/22:1 C45H86NO8P 800.6 659.6 29.00 Positive 125 5 20 20 30
PE 40:2; PE 22:0/18:2 C45H86NO8P 800.6 659.6 29.10 Positive 125 5 20 20 30
(Continued)
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Name Formula Precursor Product Retention Ion Event Dwell Q1 Pre Collision Q3 Pre
m/z m/z time [min] mode ID time [ms] bias [V] energy [V] bias [V]
PE 40:3; PE 18:1/22:2 or
22:1/18:2
C45H84NO8P 798.6 657.6 28.00 Positive 126 5 20 20 30
PE 40:4; PE 18:0/22:4 or
20:0/20:4
C45H82NO8P 796.6 655.6 27.02 Positive 127 5 20 20 30
PE 40:5; PE 18:0/22:5 C45H80NO8P 794.6 653.6 26.03 Positive 128 5 20 20 30
PE 40:6; PE 18:0/22:6 C45H78NO8P 792.6 651.6 25.54 Positive 129 5 20 20 30
PE 40:6; PE 18:1/22:5 C45H78NO8P 792.6 651.6 25.15 Positive 129 5 20 20 30
PE 40:7; PE 18:1/22:6 C45H76NO8P 790.5 649.5 24.35 Positive 130 5 20 20 30
PE 42:5; PE 22:1/20:4 C47H84NO8P 822.6 681.6 28.00 Positive 131 5 20 20 30
PE 42:7; PE 20:1/22:6 C47H80NO8P 818.6 677.6 26.00 Positive 132 5 20 20 30
PE 42:8; PE 20:2/22:6 C47H78NO8P 816.6 675.6 25.00 Positive 133 5 20 20 30
4-Cholesten-3-one C27H44O 385.3 108.8 23.26 Positive 134 5 19 10 19
5α-Cholestan-3-one C27H46O 387.2 94.9 25.60 Positive 135 5 24 10 24
Acylcarnitine 2:0 C9H17NO4 204.1 85.05 0.98 Positive 136 5 10 21 16
Acylcarnitine 4:0 C11H22NO4 233.2 85.05 0.98 Positive 137 5 12 21 16
Acylcarnitine 6:0 C13H26NO4 261.2 85.05 1.20 Positive 138 5 14 22 16
Acylcarnitine 8:0 C15H30NO4 289.2 85.05 1.50 Positive 139 5 15 22 16
Acylcarnitine 10:0 C17H34NO4 317.3 85.05 2.21 Positive 140 5 16 22 16
Acylcarnitine 12:0 C19H38NO4 345.3 85.05 3.72 Positive 141 5 17 23 16
Acylcarnitine 14:0 C21H42NO4 373.3 85.05 6.37 Positive 142 5 18 26 16
Acylcarnitine 14:1 C21H40NO4 371.3 85.05 4.59 Positive 143 5 18 26 16
Acylcarnitine 16:0 C23H46NO4 401.4 85.05 9.62 Positive 144 5 19 27 16
Acylcarnitine 16:1 C23H44NO4 399.3 85.05 7.40 Positive 145 5 19 27 16
Acylcarnitine 18:0 C25H50NO4 429.4 85.05 13.04 Positive 146 5 21 28 16
Acylcarnitine 18:1 C25H48NO4 427.4 85.05 10.59 Positive 147 5 21 28 16
Acylcarnitine 18:2 C25H46NO4 425.4 85.05 8.57 Positive 148 5 21 28 16
FFA 12:0 (Lauric acid) C12H24O2 199 199 4.53 Negative 149 5 25 10 25
FFA 13:0 (Tridecanoic
acid)
C13H26O2 213.2 213.2 5.50 Negative 150 5 17 10 20
FFA 14:0 (Myristic acid) C14H28O2 227.1 227.1 7.52 Negative 151 5 15 10 15
FFA 14:1 (Myristoleic
acid, n–5)
C14H26O2 225.2 225.2 5.44 Negative 152 5 15 10 15
FFA 15:0 (Pentadecylic
acid)
C15H30O2 240.8 240.8 9.10 Negative 153 5 16 10 16
FFA 16:0 (Palmitic acid) C16H32O2 255.05 255.05 11.02 Negative 154 5 17 10 17
FFA 16:1 (Palmitoleic
acid, n–7)
C16H30O2 253.1 253.1 10.59 Negative 155 5 15 10 15
FFA 17:0 (Margaric acid) C17H34O2 268.9 268.9 12.75 Negative 156 5 13 10 13
FFA 17:1
(cis-10-Heptadecanoic
acid, n–7)
C17H32O2 267.2 267.2 10.25 Negative 157 5 12 10 12
FFA 18:0 (Stearic acid) C18H36O2 283.05 283.05 14.45 Negative 158 5 18 10 15
FFA 18:1 (Oleic acid, n–9
or cis-Vaccenic acid, n–7)
C18H34O2 280.9 280.9 11.86 Negative 159 5 12 10 12
FFA 18:1 (Elaidic acid,
n–9 or trans-Vaccenic
acid, n–7)
C18H34O2 280.9 280.9 12.40 Negative 159 5 19 10 19
FFA 18:2 (Linoleic acid,
n–6)
C18H32O2 278.95 278.95 9.76 Negative 160 5 21 10 21
FFA 18:3 (α-Linolenic
acid, n–3 or γ-Linolenic
acid, n–6)
C18H30O2 276.9 276.9 8.31 Negative 161 5 18 10 15
(Continued)
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Name Formula Precursor Product Retention Ion Event Dwell Q1 Pre Collision Q3 Pre
m/z m/z time [min] mode ID time [ms] bias [V] energy [V] bias [V]
FFA 18:4 (Stearidonic
acid, n–3)
C18H28O2 275.2 275.2 6.71 Negative 162 5 18 10 15
FFA 19:0
(Tuberculostearic acid)
C19H38O2 296.9 296.9 16.20 Negative 163 5 14 10 14
FFA 20:0 (Arachidic acid) C20H40O2 311 311 17.52 Negative 164 5 14 10 14
FFA 20:1
(cis-11-Eicosenoic acid,
n–9)
C20H38O2 309.3 309.3 15.14 Negative 165 5 14 10 14
FFA 20:2
(cis-11-14-Eicosadienoic
acid, n–6)
C20H36O2 307.3 307.3 13.01 Negative 166 5 10 10 10
FFA 20:3
(Dihomo-γ-linolenic acid,
n–6 or Mead acid, n–9)
C20H34O2 305.05 305.05 11.20 Negative 167 5 18 10 15
FFA 20:4 (Arachidonic
acid, n–6)
C20H32O2 303.1 303.1 9.96 Negative 168 5 18 10 15
FFA 20:5
(Eicosapentaenoic acid,
n–3)
C20H30O2 300.9 300.9 8.27 Negative 169 5 22 10 22
FFA 21:0 (Heneicosanoic
acid)
C21H42O2 325.3 325.3 18.85 Negative 170 5 18 10 15
FFA 22:0 (Behenic acid) C22H44O2 339.3 339.3 20.40 Negative 171 5 18 10 15
FFA 22:1 (Erucic acid,
n–9)
C22H42O2 337 337 17.94 Negative 172 5 18 10 15
FFA 22:4
(Docosatetraenoic acid,
n–6)
C22H36O2 331.3 331.3 12.75 Negative 173 5 18 10 15
FFA 22:5
(Docosapentaenoic acid,
n–6)
C22H34O2 329.2 329.2 11.52 Negative 174 5 16 10 16
FFA 22:6
(Docosahexaenoic acid,
n–3)
C22H32O2 326.95 326.95 9.84 Negative 175 5 18 10 15
FFA 23:0 (Tricosanoic
acid)
C23H46O2 353.3 353.3 21.20 Negative 176 5 18 10 15
FFA 24:0 (Lignoceric acid) C24H48O2 367.4 367.4 22.31 Negative 177 5 18 10 15
FFA 24:1 (Nervonic acid,
n–9)
C24H46O2 365.3 365.3 20.35 Negative 178 5 18 10 15
FFA 25:0 (Pentacosanoic
acid)
C25H50O2 381.4 381.4 22.97 Negative 179 5 18 10 15
FFA 26:0 (Cerotic acid) C26H52O2 395.4 395.4 24.27 Negative 180 5 18 10 15
FFA 27:0 (Heptacosanoic
acid)
C27H54O2 409.4 409.4 25.18 Negative 181 5 18 10 15
FFA 28:0 (Montanic acid) C28H56O2 423.3 423.3 26.19 Negative 182 5 19 10 19
Cholic acid; CA (Cholic
acid)
C24H40O5 407.1 407.1 2.47 Negative 183 5 29 10 29
Cholic acid; CDCA
(Chenodeoxycholic acid)
C24H40O4 391.3 391.3 4.02 Negative 184 5 18 10 18
Cholic acid; UDGA
(Ursodeoxycholic acid)
C24H40O4 391.3 391.3 2.12 Negative 184 5 18 10 18
Cholic acid; GCA
(Glycocholic acid)
C26H43NO6 464.5 464.5 2.00 Negative 185 5 12 10 12
Cholic acid; GCDCA
(Glycochenodeoxycholate)
C26H43NO5 448.1 448.1 2.81 Negative 186 5 30 10 30
(Continued)
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Name Formula Precursor Product Retention Ion Event Dwell Q1 Pre Collision Q3 Pre
m/z m/z time [min] mode ID time [ms] bias [V] energy [V] bias [V]
Cholic acid; GDCA
(Glycodeoxycholate)
C26H43NO5 448.1 448.1 3.05 Negative 186 5 30 10 30
Cholic acid; LCA
(Lithocholic acid)
C24H40O4 375.1 375.1 5.64 Negative 187 5 26 10 26
Cholic acid; TCA
(Taurocholate)
C26H45NO7S 514.3 514.3 1.94 Negative 188 5 24 10 24
Cholic acid; TCDCA
(Taurochenodeoxycholate)
C26H45NO6S 498.5 498.5 2.59 Negative 189 5 23 10 23
Ether-linked isobaric species of plasmanyl (e) and plasmenyl (p) analogs of glycerophospholipids. Acyl positions of glycerolipids (sn-1 and sn-2).
Double bond positions (n).
IS, Internal Standard.
Q1 and Q3 pre-bias are the characteristic parameters of Shimadzu instrument.
FIGURE 2 | Identification and quantification results from isotopic peak
estimations. This example demonstrates how the isotopic peaks affect
compound identifications and quantifications. The 13.798 and 13.786% of the
monoisotopic peak abundances of PC 37:5e and PC 37:5p are theoretically
monitored at the M+2 MRM transition. As shown in the bottom-left figure,
two detected peaks eluted at 25.4 and 26.1min were derived from 100 and
16% of the respective monoisotopic ions. This result shows that the isotopic
peaks should be estimated for compound identifications and quantifications.
improving. The combination of MRM-DIFF and QSRR meth-
ods may ease the tedious task of molecular identification in the
future. Indeed, the sensitivity and selectivity of triple quadrupole
MS for lipids far exceeded those of TOF- or Orbitrap-MS with
respect to the identified lipids (data not shown). The reliability of
quantification can be therefore improved by the higher signal to
noise ratio. On the other hand, high-resolution MS systems have
the advantage in its qualitative aspect: the O-alkyl or O-alkenyl
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FIGURE 3 | Alignment results from two different reference files.
The upper figure shows raw chromatograms; the blue and gray
lines describe pooled QCs and biological samples, respectively. As
shown in the bottom figures, alignment accuracy is considerably
affected by the selected reference file. The automatic reference
selection method in combination with pooled QC datasets robustly
picks the suitable reference file. This contributes to better-aligned
results.
derivatives can be distinguished from standard acyl derivatives by
accurate masses.
We introduced MRM-DIFF as a differential analysis tool for
large-scale MRM assays of up to 200 datasets. However, the clas-
sical “widely targeted” approach remains important for analyzing
lipids by MRM assays. We developed another software program,
MRMPROBS, to support the analysis of MRM assays by set-
ting two or three transitions for each molecular target (Tsugawa
et al., 2014). Either of the two software programs, MRM-DIFF
or MRMPROBS, can be chosen depending on the research
needs.
MATERIALS AND METHODS
REAGENTS AND CHEMICALS
Human-, mouse-, and rat-sera were purchased from Sigma-
Aldrich Co. (St. Louis,MO,USA), authentic standard compounds
from Sigma-Aldrich and Avanti Polar Lipids, Inc. (Alabaster,
AL, USA), and ammonium acetate from Sigma-Aldrich. LC/MS
grade distilled water and LC/MS grade methanol were pur-
chased from Wako Pure Chemical Industries Ltd. (Osaka,
Japan).
SAMPLE PREPARATION
Lipid extraction from the sera was as described previously
(Yamada et al., 2013) with minor modifications. Briefly, 10μL
of serum were mixed into 90μL of methanol containing 10μL
of PC 12:0/12:0 (0.5μg mL−1) as the internal standard. After
vortexing at the maximum setting for 1min, the samples were
placed on ice for 10min. The extracts were then centrifuged at
16,000× g for 5min at 4◦C and the resulting supernatant (60μL)
was recovered. QC sample (150μL) was prepared bymixing equal
amounts (10μL each) of human-, mouse-, and rat-serum extract
(n = 5).
LC/MS/MS CONDITIONS
The LC/MS/MS system was comprised of a Shimadzu Nexera
ultra-high-performance liquid chromatograph and a Shimadzu
LCMS-8040 triple quadrupole mass spectrometer equipped with
an ESI ion source (Shimadzu Co., Kyoto, Japan). The condi-
tions for LC/MS/MS analysis were: column, InertSustain (2.1 ×
150mm; particle size, 3μm; GL Sciences Inc., Tokyo, Japan);
column temperature, 40◦C; mobile phase, 20mM ammonium
acetate in water (A) or methanol (B); flow rate, 0.35mL min−1;
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FIGURE 4 | Differences in PCA score plots of internal standard- and
LOESS/cubic spline-based normalizations. (A) The metabolite signals
were normalized by one internal standard PC (12:0/12:0). (B) The
metabolite signals were corrected by LOESS and cubic spline in
combination with the abundances of pooled QC datasets that were
analyzed at every five biological samples. This result shows that the
clusters of each serum class were much improved with LOESS and cubic
spline normalization.
gradient curve, 75% B at 0min, 99% B at 22min, 99% B at
39min, 75% B at 39.1min, and 75% B at 45min; injection vol-
ume, 2μL; mass analysis mode, both positive and negative ion
mode with a polarity switching time of 15ms; electrospray volt-
age, 4.5 kV for positive- and −3.5 kV for negative-ion mode;
nebulizer gas flow, 3.0 L min−1; drying gas flow, 15.0 L min−1;
desolvation temperature, 250◦C; heat block temperature, 400◦C;
and detector voltage, 1.62 kV. The MRM mode with a dwell time
of 5ms per channel was used. Other optimized MRM parameters
for each lipid and its related metabolite are shown in Table 1. One
pooled QC sample was repeatedly analyzed at each fifth sample
injection in this study.
IDENTIFICATION OF LIPIDS
Major glycerophospholipids such as phosphatidylcholine (PC),
phosphatidylethanolamine (PE), lysophosphatidylcholine
(lysoPC), and lysophosphatidylethanolamine (lysoPE) manifest
a wide variety of structures with a hydrophilic head group and/or
hydrophobic fatty acid tails that include isobaric and isomeric
lipid molecular species in the serum. The workflow for the iden-
tification of the glycerophospholipids in the human serum using
the LC/MS/MS system is shown in Supplementary Figure 1. In
short, the selection of glycerophospholipid candidates was based
on previously reported information (Quehenberger et al., 2010)
and our experimental findings with LC/MS/MS based virtual
MRM screening (Supplementary Tables 1, 2). Identification of
the PC, PE, lysoPC, and lysoPE molecular species on a triple
quadrupole mass spectrometer requires the detection of specific
fragment ions derived from both the head group (phospho-
choline, m/z 184.1 or phosphatidylethanolamine, m/z M-140.0)
in the positive-ion mode and the fatty acid (FA) moieties in the
negative-ion mode. Therefore, after the head group moieties of
targeted glycerophospholipids were confirmed by LC/MS/MS
with MRM in the positive-ion mode, the FA moieties of targeted
glycerophospholipids were identified by product-ion scanning
on the triple quadrupole mass spectrometer in the negative-ion
mode. In some cases, more than two different molecular species
(structural isomers) were detected within the same m/z peaks,
which was difficult to separate by our LC condition. Additionally,
to distinguish plasmanyl (e) and plasmenyl (p) analogs of
glycerophospholipids, the acid hydrolysis analysis was performed
according to the previous report (Taguchi and Ishikawa, 2010).
Structural characterization of two lysoglycerophospholipid
regioisomers such as 2-acyl-1-lysophospholipids (e.g., lysoPC
14:0 sn-2) and 1-acyl-2-lysophospholipids (e.g., lysoPC 14:0
sn-1) was also performed using C18-based reverse phase column
chromatography (Okudaira et al., 2014). Other lipids such as
free fatty acid (FFA), acylcarnitine (AC), cholesterol, and cholic
acid (CA) were identified on the basis of the manual curation
with their authentic standards. Finally, the compound name, the
molecular formula, the MRM transition, and the RT of 284 lipids
molecular species were stored in the user-defined lipids library
(Table 1).
MRM-DIFF SOFTWARE AND DATA PROCESSING PARAMETERS
The MRM-DIFF program, the demonstration data set, and the
tutorial are downloadable at the “Standalone software” section
of PRIMe (Platform for RIKEN Metabolomics, http://prime.psc.
riken.jp/) database website. MRM-DIFF can import two data for-
mats: “Analysis Base File” (ABF) format converted by our file
converter (Tsugawa et al., 2014) and the common mzML for-
mat converted by the ProteoWizardMSConvert software (Kessner
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et al., 2008). The ABF file converter is freely available at http://
www.reifycs.com/english/AbfConverter/.
MRM-DIFF is available in Windows OS (.NET Framework 4.0
or later; RAM: 4.0GB or more). Its source code was written in the
C# language with the Windows Presentation Foundation (WPF)
to develop the graphical user interface.
In this study, Shimadzu LCD files were converted to ABF for-
mat by our converter. The reference library for lipid identification
was prepared from the above identification criteria and the library
is downloadable at our RIKEN PRIMe website. After import-
ing ABF files in the MRM-DIFF program, data processing was
performed with the following parameters: smoothing method,
linear weighted moving average; smoothing level, 2 scan; mini-
mum peak width, 5 scan; minimum peak height, 100 amplitude;
retention time tolerance, 0.2min; minimum posterior, 70%; col-
umn type, ODS; segment size, 0.5min; slack parameter, 1 scan;
border limit, constant. The other details for theMRM-DIFF oper-
ation were described in the MRM-DIFF tutorial (http://prime.
psc.riken.jp/).
THEORY
This section describes the mathematical methods implemented
in the MRM-DIFF software program. MRM-DIFF accepts two
data formats: the mzML data format converted via ProteoWizard
and the ABF data format converted via our file converter program
(Tsugawa et al., 2014). After importing all data files, the reference
file is automatically selected by means of pooled QC datasets for
each MRM transition as in the equation.
Chromatographic centroid =
∑
(abundance (n) ∗
retention time(n))∑
abundance(n)
where n indicates the scan number of the chromatogram data
points. This equation calculates the “gravity” of each chro-
matogram. MRM-DIFF selects a reference file whose value is
closest to the midpoint between the minimum and the maximum
of pooled QCs gravities.
We implemented COW (Nielsen et al., 1998) in the MRM-
DIFF program as the non-linear alignment algorithm. Three
parameters are required for chromatogram alignments, the seg-
ment size, warp slack, and a targeted reference chromatogram.
The most important chore, selection of the reference chro-
matogram, is performed with the chromatographic centroid algo-
rithm. Based on our experience, the segment size and warp slack
parameters should be set to “peak widths (min)” and “1 or
2,” respectively, as long as reverse phase LC methods are used
for lipid profiling. We also looked for suitable parameters for
hydrophilic interaction chromatography (HILIC)- and pentaflu-
orophenylpropyl (PFPP) columns; the recommended parame-
ters are described in the MRM-DIFF tutorial (http://prime.psc.
riken.jp/).
The peak detection algorithm is performed in the MRM-DIFF
program. The principle underlying the peak detectionmethod for
pattern recognition is: (1) The peak detection method is applied
to one representative chromatogram. The peak detection algo-
rithm is the same as in our previous report (Tsugawa et al.,
2014). (2) Peak detections for other chromatograms are based
on a representative chromatogram; we call the “data dependent
peak detection method.” (3) In this method, the local maximum
within the left- and right edges of the representative peak is rec-
ognized as the peak top in the other chromatograms. (4) The left-
and right edge of other chromatograms now corresponds with the
representative peak in the MRM-DIFF program. Local minimum
search from the assigned peak top is an alternative option. We
highly recommend the peak height as the quantification value for
detected peaks.
In theMRM-DIFF program, compound identification is based
on retention time accuracy:
Retention time accuracy = exp
{
−0.5 ×
(
RTact. − RTlib.
δ
)2}
RTact. and RTlib. indicate the measured- and reference reten-
tion time, respectively, and the σ value is the user-defined search
tolerance. The value range is from 0 (non-consistency) to 1
(confidential); 0.7 is the default threshold for compound identifi-
cations. The criteria for isotopic ion estimation are: (1) isotopic
ions up to M+6 are estimated. (2) MRM transitions includ-
ing the same product ion are examined. (3) The abundance
peaks higher than the monoisotopic ion are not recognized as
the isotopic peaks. (4) Peak top differences within 1 s from the
peak top of monoisotopic ions are recognized as the isotopic
peaks.
In addition, the isotopic peak abundances are calculated
by the theoretical isotopic ratio of the molecular formula
with the following method [Tsugawa et al. (2014). MS-DIAL:
Data Independent MS/MS Deconvolution for Comprehensive
Metabolome Analysis, submitted]. For example, the isotopic
ratio for C42H82NO8P, i.e., PC(16:0/18:1), is represented as
the coefficient values of expanded elements of the following
equation.
(12C+13C)42(1H+2H)82(14N+15N)1(16O+17O+18O)8(31P)1 =
[12C142H8214N116O831P1]
(
1+
13C
12C
)42(
1+
2H
1H
)82(
1+
15N
14N
)1
(
1+
17O
16O
+
18O
16O
)8
The letter such as 12C indicates the natural abundance of each
element. The above contents except for the mono-isotopic mass
12C421H8214N16O831P are expanded. The coefficient value of each
expanded term represents the relative isotope abundances with
respect to the mono-isotopic ion. Since only nominal masses are
output from the triple quadrupole MS system, the theoretical
abundances are binned into nominal values.
Finally, the LOESS/cubic spline method was implemented as
described in our previous report (Tsugawa et al., 2014). Note that
the MRM-DIFF program does not require pooled QC datasets.
The QC datasets can be alternated with other files given the
above mathematical details. However, the LOESS/cubic spline
normalization method cannot be applied.
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